Your browser doesn't support javascript.
loading
Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation.
Chan, Denice T Y; Jenkinson, Lesley; Haynes, Stuart W; Austin, Mark; Diamandakis, Agata; Burschowsky, Daniel; Seewooruthun, Chitra; Addyman, Alexandra; Fiedler, Sebastian; Ryman, Stephanie; Whitehouse, Jessica; Slater, Louise H; Gowans, Ellen; Shibata, Yoko; Barnard, Michelle; Wilkinson, Robert W; Vaughan, Tristan J; Holt, Sarah V; Cerundolo, Vincenzo; Carr, Mark D; Groves, Maria A T.
Afiliação
  • Chan DTY; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Jenkinson L; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Haynes SW; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Austin M; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Diamandakis A; Antibody Discovery & Protein Engineering, BioPharmaceuticals Research & Development, AstraZeneca, CB21 6GH Cambridge, United Kingdom.
  • Burschowsky D; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Seewooruthun C; Leicester Institute of Structural and Chemical Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Addyman A; Department of Molecular and Cell Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Fiedler S; Leicester Institute of Structural and Chemical Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Ryman S; Department of Molecular and Cell Biology, University of Leicester, LE1 7HB Leicester, United Kingdom.
  • Whitehouse J; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Slater LH; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Gowans E; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Shibata Y; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Barnard M; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Wilkinson RW; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Vaughan TJ; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Holt SV; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
  • Cerundolo V; Early Oncology Discovery, Oncology Research & Development, AstraZeneca, CB21 6GH Cambridge, United Kingdom.
  • Carr MD; Antibody Discovery & Protein Engineering, BioPharmaceuticals Research & Development, AstraZeneca, CB21 6GH Cambridge, United Kingdom.
  • Groves MAT; Cancer Research UK-AstraZeneca Antibody Alliance Laboratory, CB21 6GP Cambridge, United Kingdom.
Proc Natl Acad Sci U S A ; 117(29): 16949-16960, 2020 07 21.
Article em En | MEDLINE | ID: mdl-32616569
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arginase / Regiões Determinantes de Complementaridade / Anticorpos / Afinidade de Anticorpos Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arginase / Regiões Determinantes de Complementaridade / Anticorpos / Afinidade de Anticorpos Limite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Ano de publicação: 2020 Tipo de documento: Article